Loading
Life sciences · Journal article
Future Microbiology · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that proposes a bidirectional mechanistic model linking gut microbiota dysbiosis to chemotherapy and radiotherapy resistance and toxicity in colorectal cancer, and suggests probiotics as a potential adjuvant strategy. The work raises a hypothesis rather than testing one, and does not present primary efficacy data, comparative outcomes, or clinical trial results to support clinical practice.
Narrative literature review. Patients with colorectal cancer undergoing chemotherapy and radiotherapy.
Gut microbiota is described as a critical determinant of both treatment response and adverse events in colorectal cancer A closed-loop model proposed in which chemotherapy and radiotherapy disrupt gut microbial homeostasis, and dysbiosis impairs therapeutic efficacy and exacerbates toxicity Probiotics are discussed as potentially restoring microecological balance, reinforcing intestinal barrier function, and modulating systemic immunity
Gut microbiota is described as a critical determinant of both treatment response and adverse events in colorectal cancer A closed-loop model proposed in which chemotherapy and radiotherapy disrupt gut microbial homeostasis, and dysbiosis impairs therapeutic efficacy and exacerbates toxicity
This review does not provide direct evidence to guide clinical decision-making about probiotic use or microbiota-directed interventions. It articulates a theoretical framework that may inform future trials but does not report efficacy or safety data from human studies.
This is a narrative review proposing a mechanistic model of microbiota-therapy interaction without reporting primary clinical trial data, efficacy outcomes, or comparative evidence.
As stated by the source record.
This review does not provide direct evidence to guide clinical decision-making about probiotic use or microbiota-directed interventions. It articulates a theoretical framework that may inform future trials but does not report efficacy or safety data from human studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Colorectal cancer remains a leading cause of cancer-related mortality worldwide. While chemotherapy and radiotherapy serve as a cornerstone of treatment, their clinical efficacy is frequently compromised by therapeutic resistance and gastrointestinal toxicity. Accumulating evidence indicates that the gut microbiota is a critical determinant of both treatment response and adverse events. This review describes a closed-loop model in which chemotherapy and radiotherapy disrupt gut microbial homeostasis, whereas microbiota dysbiosis in turn impairs therapeutic efficacy and exacerbates treatment-related toxicity, thereby establishing an interaction between therapy and the gut microbiota. Probiotics are discussed as a microbiota-directed adjuvant strategy. By restoring microecological balance, reinforcing intestinal barrier function, and modulating systemic immunity, these interventions may provide dual benefits by sensitizing tumors to chemotherapy and radiotherapy and mitigating treatment-related toxicity. Overall, clarifying and therapeutically leveraging this microbiota-chemotherapy and radiotherapy interaction may provide a rational avenue to improve the therapeutic index of chemotherapy and radiotherapy. [PubMed and Web of Science, database inception to January 2026].
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.